Replimune’s Twice‑Rejected Melanoma Drug Prevails in FDA Adcomm Vote on July 31, 2026 Advanced Melanoma Advisory Committees Cellular Tissue gene therapy melanoma drug nivolumab Opdivo Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +
Huyabio scores with Opdivo combo in 'milestone' skin cancer trial on July 14, 2026 Advanced Melanoma Combined Modality Therapy epigenetic immunomodifier Frequency of Responses Huyabio Malignant neoplasm of skin Metastatic melanoma nivolumab Opdivo Overall Survival Phase 2 Phase 3 Unresectable +
Replimune to ask FDA for re‑review of melanoma drug, as agency stands by past rejections on May 29, 2026 Accelerated Advanced Melanoma Approved Complete Response Letter IGNYTE melanoma drug nivolumab Opdivo Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +
FDA Approves Opdivo (Nivolumab) for Classical Hodgkin Lymphoma Indications on March 24, 2026 Approved Autolysosome Combined Hodgkin Disease Immunotherapy Myers Squibb nivolumab Opdivo United States Food and Drug Administration +
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure on December 16, 2025 Arcus Biosciences domvanalimab Esophageal Neoplasms Gilead Sciences Malignant neoplasm of stomach nivolumab Opdivo STAR-221 TIGIT gene zimberelimab +
Ono's BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial on October 10, 2025 Advanced phase Bristol-Myers Squibb EP4 antagonist EP4 Antagonist ONO-4578 Episodic HER2-negative Malignant neoplasm of stomach nivolumab Opdivo Pharmacotherapy Phase 2 Progression-Free Survival +
Survival Benefit of Amgen's Bemarituzumab in Gastric Cancer Attenuates at Final Analysis on September 05, 2025 Amgen Attenuated by (contextual qualifier) bemarituzumab Benefit final analysis FORTITUDE-101 FORTITUDE-102 Malignant neoplasm of stomach nivolumab Opdivo Overall Survival Zai Lab +
Replimune Awaits FDA Direction After Complete Response Letter for Advanced Melanoma Therapy on August 04, 2025 Advanced Melanoma Cancer Therapeutic Procedure Complete IGNYTE trial nivolumab Replimune Response Letter RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +